Using the azoxymethane/dextran sodium sulfate model, Armstrong and colleagues showed that estrogen treatment reduced expression of ERβ while increasing ERα (68), and a similar finding was previously reported in rats treated with soy isoflavonoids (69), suggesting that the ratio of ERβ/ERα might have clinical implications in protecting against CRC (70). Here, ESR2 is linked to colorectal carcinoma.